Athyrium Capital Management

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden, dedicated to developing and commercializing treatments for patients with significant unmet medical needs, particularly in niche indications. The company is primarily focused on its product candidate, Nefecon, which features a patented formulation designed to deliver budesonide directly to the target area, aiming to treat IgA nephropathy, an inflammatory renal disease. Calliditas is currently conducting a global Phase 3 clinical trial for Nefecon and plans to bring the medication to market in the United States. Additionally, the company is exploring novel treatments for orphan indications, with a particular emphasis on renal and hepatic diseases.

Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company based in Basel, Switzerland, that focuses on developing innovative therapeutic products in the fields of oncology and anti-infectives. The company offers isavuconazole, marketed under the brand name Cresemba, an antifungal drug used to treat invasive aspergillosis and mucormycosis. Additionally, Basilea provides ceftobiprole, an intravenous antibiotic for community and hospital-acquired pneumonia, which is also undergoing Phase III clinical trials for other serious bacterial infections. The company is actively developing several candidates, including Derazantinib, for intrahepatic cholangiocarcinoma, and BAL101553 and BAL3833, which target various tumor types and cancer pathways. Through its integrated research and commercial operations, Basilea aims to address the growing challenges of antibiotic resistance and the limitations of current treatment options.

uMotif Limited is a company specializing in data capture solutions for the healthcare industry. Established in 2012 and based in London, the company operates a patient-centered data capture platform that facilitates modern clinical research. uMotif’s application enables the capture and validation of various types of patient-generated data, including electronic consent, electronic clinical outcome assessments (eCOA), electronic patient-reported outcomes (ePRO), patient-reported outcome measures (PROM), and patient-reported experience measures (PREM). This technology serves a diverse range of clients, including pharmaceutical companies, medical device firms, biotechnology companies, contract research organizations (CROs), and academic institutions. By providing tools that enhance data collection, uMotif allows researchers and clinicians to gather rich health data across multiple conditions, ultimately supporting advancements in clinical research and patient care.

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.

Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company headquartered in Bridgewater, New Jersey, specializing in the development and commercialization of pharmaceutical products primarily in the United States, Argentina, and Hungary. The company offers a diverse portfolio of products, including M-72, an extended-release tablet for attention deficit hyperactivity disorder (ADHD), and Osmolex ER, an extended-release tablet for Parkinson's disease and drug-induced extrapyramidal reactions. Other significant offerings include Lorzone for muscle spasms, ConZip for pain management, and Arbaclofen, which is currently in phase III clinical trials for multiple sclerosis spasticity. Osmotica also focuses on women's health with products like Divigel for menopause and OB Complete for prenatal care, alongside various other branded and generic medications targeting conditions such as hypertension and overactive bladder. The company employs its proprietary osmotic technology platform to enhance the efficacy of its pharmaceutical products, maintaining operations that include manufacturing facilities in the United States and Spain.

Puma Biotechnology is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. The company focuses on acquiring and advancing drug candidates that have completed initial clinical testing. Its primary product, NERLYNX, is an oral formulation of neratinib, which is used for treating HER2-positive breast cancer. In addition to neratinib, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets epidermal growth factor receptors HER1, HER2, and HER4. The company has established a licensing agreement with Pfizer for the development and commercialization of these drug candidates. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology is committed to enhancing treatment outcomes for patients with various forms of cancer.

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel oral and small-molecule medicines to address rare diseases with significant unmet medical needs. The company's first approved product, RAPIVAB, is an intravenous neuraminidase inhibitor for treating acute uncomplicated influenza, marketed under various names globally. BioCryst has developed ORLADEYO, an oral medication approved for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and older, and is currently under regulatory review in additional regions. The company is advancing several other product candidates, including BCX9930, an oral Factor D inhibitor for complement-mediated diseases; BCX9250, an ALK-2 inhibitor for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA-dependent RNA polymerase inhibitor aimed at treating various RNA viruses. Founded in 1986 and headquartered in Durham, North Carolina, BioCryst engages in collaborations with various institutions and organizations to enhance its research and development efforts across infectious and inflammatory diseases.

ArisGlobal LLC is a leading developer of cloud-based software solutions tailored for the life sciences industry, headquartered in Stamford, Connecticut. Founded in 1987, the company offers a comprehensive platform known as LifeSphere, which enhances the research and development process by integrating functionalities across pharmacovigilance, regulatory affairs, clinical operations, and medical information. LifeSphere encompasses a suite of tools designed to automate core functions such as case management, compliance, and reporting, enabling life sciences organizations to accelerate product development and improve safety outcomes. ArisGlobal serves over 250 clients, including biopharmaceutical companies, contract research organizations, and government health authorities, with an emphasis on streamlining collaboration among cross-functional teams. The company maintains regional offices in multiple locations worldwide, including Europe, India, Japan, and China, reinforcing its position as a global market leader in life sciences software solutions.

Secura Bio is an integrated biopharmaceutical company founded in 2019 and headquartered in Las Vegas, Nevada, with additional operations in San Diego. The company is dedicated to developing and commercializing innovative therapies, particularly in the oncology sector, to provide patients with access to life-changing treatments. By focusing on significant oncology therapies, Secura Bio aims to enhance the ability of healthcare providers to diagnose and treat serious illnesses, ultimately improving patient outcomes.

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Agendia, Inc. is a biotechnology company based in Irvine, California, founded in 2003. The company specializes in developing and distributing genomic-based diagnostic kits aimed at improving cancer treatment for patients. Agendia's molecular diagnostic technology offers insights into a patient's genomic profile, allowing physicians to make informed decisions regarding personalized treatment plans. The company's breast cancer tests utilize a comprehensive analysis of the human genome to evaluate individual risks for metastasis and determine the most appropriate therapies. This includes identifying which patients would benefit from chemotherapy or hormonal treatments, as well as those who may avoid more aggressive interventions in favor of less intensive and cost-effective options.

Sound Physicians is a healthcare company focused on enhancing the quality of inpatient care through its network of over 1,000 hospitalist and post-acute physicians. The company partners with more than 70 hospitals and an increasing number of post-acute care centers across the United States. It provides a range of services that span the acute episode of care, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By offering these comprehensive solutions, Sound Physicians aims to improve patient satisfaction and financial performance for its hospital partners, ultimately driving better outcomes in healthcare delivery.

Veloxis is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. Envarsus® is a once-daily dosage version of tacrolimus, the market-leading primary immunosuppressant in the transplant market, and has successfully demonstrated non-inferiority compared to Prograf® in its two Phase III clinical trials, Study 3001 (stable kidney transplant patients) and Study 3002 (de novo kidney transplant patients). In April 2013, the company submitted a marketing authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. In December 2013, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and enrolled over 1000 patients, including two pivotal clinical trials, studies 3001 and 3002. At the same time, Envarsus® was granted Orphan Drug status by the FDA for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The company is using its proprietary MeltDose technology in the formulation of Envarsus® to enhance the bioavailability of the drug and allow for a sustained or modified release plasma profile. The MeltDose technology has been validated in clinical studies through FDA approval of Fenoglide (now on the market) for the treatment of dyslipidemia in adults. Veloxis was founded in June 2002 as a spin-off from H. Lundbeck A/S and is listed on NASDAQ OMX Copenhagen A/S (OMX: VELO). Veloxis is an international company with headquarters in Hørsholm, Denmark, and a fully owned subsidiary in New Jersey, U.S.

VillageMD is a healthcare management services company focused on supporting primary care physicians. Founded in 2013 and headquartered in Chicago, Illinois, the company provides a comprehensive platform that includes tools, technology, operations, and staffing support. It collaborates with physician groups, independent practice associations, and health systems to enhance quality of care, improve patient experiences, and reduce costs. VillageMD's services encompass management, clinical innovation, analytics, and value-based contract negotiation, enabling healthcare providers to achieve better clinical outcomes across various populations. The company operates in multiple markets, including Chicago, Georgia, Houston, Indianapolis, Kentucky, Michigan, New Hampshire, and Austin.

OptiNose is a specialty pharmaceutical company dedicated to developing and commercializing nasal drug delivery technologies and combination drug/device therapies. The company’s proprietary Bi-Directional Delivery system enhances the efficiency of drug administration to the nasal cavity, ensuring that a significant portion of the medication is deposited in the upper posterior regions, rather than the lungs. This innovative approach has been shown to provide a faster onset of action, greater therapeutic effects with lower doses, and reduced side effects in clinical trials. One of its key products, XHANCE, is a nasal spray containing fluticasone propionate, specifically designed to treat chronic rhinosinusitis with nasal polyps by delivering medication directly to the site of inflammation. OptiNose operates offices in Norway and the UK, focusing on patients supported by ear, nose, and throat specialists, as well as allergy professionals.

Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief. It was founded in 2007 and headquartered in Malvern, Pennsylvania.

Biora Therapeutics is a biotechnology company focused on developing oral biotherapeutics that combine drug and device technologies. The company aims to enhance treatment approaches by enabling targeted delivery of therapeutics directly to the gastrointestinal tract, which is particularly beneficial for patients with Inflammatory Bowel Disease (IBD). Additionally, Biora Therapeutics is working on systemic delivery methods that facilitate needle-free, oral administration of biotherapeutics, thereby improving patient compliance and comfort. By innovating in the field of oral drug delivery, Biora Therapeutics seeks to transform therapeutic outcomes and enhance the overall patient experience.

Pharmaceutics International, Inc. is a contract development and manufacturing organization specializing in dosage form development and cGMP manufacturing services for the biotech and specialty pharmaceutical sectors, both in the United States and internationally. Established in 1994 and headquartered in Hunt Valley, Maryland, the company produces a diverse array of dosage forms, including conventional and controlled-release tablets, soft gels, inhalation products, sterile injectables, and various liquid formulations. Additionally, Pharmaceutics International offers comprehensive services such as pre-formulation, clinical trial materials manufacturing, commercial manufacturing, and clinical packaging and labeling. With a focus on enhancing drug quality and patient outcomes, the company employs advanced technologies for bioavailability enhancement and provides regulatory and project management support to its clients, thereby minimizing risks in drug development.

Medicrea is a specialized spinal implant company committed to delivering innovative technologies for the global healthcare market. With over 18 years of experience, the company offers a comprehensive range of patented products designed to enhance patient outcomes and support healthcare professionals. Medicrea develops personalized analytical services and implant systems aimed at providing long-lasting pain relief for patients undergoing spinal surgery. Its product portfolio includes the UNiD Adaptive Spine Intelligence technology, as well as the PASS Range, Cervical Range, and TH-LUMBAR Range, each tailored to meet specific clinical needs.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of innovative therapies that target the extracellular matrix, particularly through its proprietary ENHANZE drug delivery technology. This technology utilizes a patented recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of various injectable biologics and small molecules. Halozyme’s product portfolio includes Hylenex recombinant, which aids in fluid administration and enhances the absorption of injected drugs. The company is advancing a range of product candidates for conditions such as breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and various autoimmune diseases. Additionally, Halozyme collaborates with major pharmaceutical companies to integrate its technology into therapeutic biologics. The company was founded in 1998 and operates internationally, primarily in the United States and Switzerland.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.

Travere Therapeutics, Inc. is a biopharmaceutical company dedicated to the identification, development, and commercialization of therapies for rare diseases, particularly in the fields of nephrology, hepatology, and metabolism. The company markets several products, including Chenodal for the treatment of gallbladder stones, Cholbam for bile acid synthesis disorders, and Thiola for cystinuria. Its key pipeline candidate, Sparsentan, is in Phase III clinical trials for focal segmental glomerulosclerosis and immunoglobulin A nephropathy, both serious kidney conditions. Additionally, Travere sponsors no-cost genetic testing to aid in the diagnosis of cholestasis in children and collaborates with patient advocacy organizations to support the needs of patients and their families. Founded in 2011 and headquartered in San Diego, California, Travere Therapeutics was previously known as Retrophin, Inc., adopting its current name in November 2020.

Pernix Therapeutics is a specialty pharmaceutical company dedicated to the development, marketing, and sale of branded and generic medications, primarily targeting the pediatric market. Its product offerings aim to enhance children's health and well-being, focusing on areas such as allergies, upper respiratory conditions, antibiotics, and dermatology issues like head lice and contact dermatitis. The company employs a sales and marketing team of approximately 55 representatives who concentrate their efforts in densely populated states, engaging pediatricians and high-prescribing physicians to promote their products. Pernix's current strategy emphasizes maximizing sales from its existing portfolio while also planning for future growth through the introduction of new products, line extensions, and formulations, as well as acquiring and licensing approved products.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, established in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to replace the function of a failing human heart in patients with advanced heart failure. The TAH-t serves as a critical bridge to heart transplantation, enabling patients to survive until a suitable donor heart becomes available. SynCardia operates primarily in the United States, European Union, and Canada, addressing a significant need in the field of cardiac care.

InnoPharma, LLC, founded in 2005 and located in Piscataway, New Jersey, is a privately held pharmaceutical research and development company. The firm specializes in the development of complex generic and innovative specialty pharmaceutical and biopharmaceutical products, particularly in injectable and ophthalmic dosage forms. InnoPharma boasts a diverse portfolio of products under development, employing a range of formulations such as suspensions, lyophilized products, emulsions, liposomes, micelles, and lipid complexes.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

TRIA Beauty, Inc. specializes in developing and selling light-based medical devices designed for consumer use in skincare and beauty treatments. The company's primary offerings include a hand-held diode laser device for permanent hair removal, a Skin Perfecting Blue Light device targeting acne-causing bacteria, a Skin Rejuvenating Laser for anti-aging, and an Age-Defying Eye Wrinkle Correcting Laser aimed at reducing fine lines around the eyes. These products leverage advanced light technology, typically used in professional dermatological treatments, allowing users to achieve salon-quality results at home. TRIA Beauty markets its products through its e-commerce platform and various indirect sales channels, including television, retail locations, and physician offices. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty serves customers across multiple countries, including the United States, Japan, and several European nations. The company previously operated under the name SpectraGenics, Inc. before rebranding in 2008.

BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, established in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to replace the function of a failing human heart in patients with advanced heart failure. The TAH-t serves as a critical bridge to heart transplantation, enabling patients to survive until a suitable donor heart becomes available. SynCardia operates primarily in the United States, European Union, and Canada, addressing a significant need in the field of cardiac care.

Verenium possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of cellulosic ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for advanced biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

BioFire Diagnostics is a clinical diagnostics company based in Salt Lake City, Utah, that focuses on detecting pathogens and mutations for molecular diagnostics. Founded in 1990, the company holds over 70 patents related to polymerase chain reaction (PCR) technology, including innovations in rapid PCR cycling. BioFire offers nearly 200 products tailored for clinical, research, and military applications. Its services are designed to provide accurate results in syndromic infectious disease diagnostics, utilizing real-time thermocycling and mutation scanning. BioFire's diagnostic panels test for a wide range of viruses, bacteria, and antimicrobial resistance genes, thereby enabling healthcare providers to assess and improve treatment outcomes for patients of all ages.